PANDA Trial Completion Puts iRhythm’s Pediatric Growth Story in Focus

Irhythm Technologies (IRTC) announced an update on their ongoing clinical study.

The Pediatric Adhesion and New Dermal Approach Study, or PANDA, tests how well iRhythm Technologies, Inc.’s Zio monitor works in children who need heart rhythm checks. The study aims to see if kids can wear the patch for up to 14 days and still get a strong signal, which matters for broader use in pediatric heart care.

The main treatment is the Zio monitor, an adhesive heart patch worn on the upper left chest like a bandage. It tracks heart rhythm and rate using a small battery-powered device so doctors can spot irregular beats in everyday life, not just in a clinic.

The study uses a single group design with all patients getting the same Zio device and no comparison arm. There is no masking, and the study’s primary goal is diagnostic, meaning it focuses on how well the patch captures usable data over the wear period.

The trial is listed as interventional and is now completed, marking a key step before any broader pediatric rollout. The latest update was submitted on 2026-05-05, which shows that iRhythm is still curating and refining data even after active enrollment and device use have ended.

For investors, a completed pediatric study is a clear milestone that can support the growth story for IRTC beyond adult monitoring. Solid results could expand the addressable market in syncope, congenital heart disease, and arrhythmias in children, and may help defend share against rivals in wearable cardiac diagnostics.

Positive traction in pediatrics could improve investor sentiment, support premium pricing, and strengthen iRhythm’s moat as payers and hospitals look for validated, kid-friendly options. The PANDA study is completed and recently updated, with further details available on the ClinicalTrials portal.